
    
      Part I: PK/PD and safety evaluation -Two regimens of ICP-022 (High dose QD and low dose BID)
      were designed for assessment of safety, as well as PK/PD profiles. The recommended dose of
      phase II clinical study will be determined according to the Part I results.

      Part II: Dose expansion -Anti-tumor effects of ICP-022 in Chinese patients with R/R MCL will
      be evaluated in approximately 80 subjects. The recommended Phase 2 dose will be used in the
      Part II.
    
  